

Use and Misuse of PRP: Clinical Trial Proposal to Help Find PRP's True Efficacy

Oriol Mirallas, Javier Farelo, Ramon Grimalt

Oriol Mirallas, Javier Farelo, Ramon Grimalt, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona

Conflict-of-interest statement: The author(s) declare(s) that there is no conflict of interest regarding the publication of this paper.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Correspondence to: Ramon Grimalt, MD, PhD, Ramon Grimalt, Associate Professor of Dermatology, Faculty of Medicine and Health, Sciences, Universitat Internacional de Catalunya, Barcelona, Catalunya.

Email: rgrimalt@uic.es

Telephone: +34 617301661

Received: December 9, 2017

Revised: February 25, 2018

Accepted: February 28, 2018

Published online: April 23, 2018

ABSTRACT

INTRODUCTION: Since the early 1970s, Platelet-rich plasma (PRP) has been used in many fields as a potential remedy for having regenerative properties. In dermatology, its use is extended to different hair diseases: alopecia areata, traction alopecia, androgenetic alopecia (AGA), and even cicatricial alopecia. Despite its increasing use in the clinical practice, the protocol used to produce PRP differs greatly between researchers and its efficacy has not been clearly demonstrated. Particularly, AGA is an illness characterized by a progressive hair thinning and miniaturization caused by the effect of dihydrotestosterone (DHT) on the hair follicle. This type of alopecia is the most common in men, increasing its incidence with age. Until

the date, there are only two efficient treatments approved by the FDA: Finasteride and Minoxidil. PRP seems to be a potential new candidate according to recent studies, but multiple PRP obtaining techniques have raised ambiguous results about the real efficacy of PRP in patients with AGA. Thus, we have elaborated a methodology to help researchers designing future clinical trials on PRP therapy. We propose a randomized clinical trial with a uniformed PRP obtaining technique in order to properly assess the PRP efficacy as a treatment for AGA.

OBJECTIVE: Analyze the objective data published until the date in order to define the real efficacy of PRP as a treatment for AGA, and offer a design of a clinical phase trial with a standardized methodology to obtain proper scientific evidence of PRP efficacy.

METHODS: Retrospective systematic review of the literature published and a randomized placebo-controlled, double-blind, half-head study clinical trial proposal with a uniformed PRP obtaining methodology to properly assess its efficacy as a future AGA treatment.

Key words: Male-pattern hair loss (MPHL); Androgenetic alopecia (AGA); Platelet-rich plasma (PRP); Efficacy; Growth factors (GFs)

© 2018 The Author(s). Published by ACT Publishing Group Ltd. All rights reserved.

Mirallas O, Farelo J, Grimalt R. Use and misuse of PRP: Clinical Trial Proposal to Help Find PRP's True Efficacy. *Journal of Dermatological Research* 2018; **2(4)**: 120-134 Available from: URL: <http://www.ghrnet.org/index.php/jdr/article/view/2213>

INTRODUCTION

Androgenetic alopecia (AGA) is an illness characterized by a progressive hair thinning and miniaturization, diminishing both the length and the diameter, transforming it in fuzz so that with time it completely atrophies and is characterised by the loss of hair from the scalp in a defined pattern. Determining factors appear to be genetic predisposition coupled with the presence of sufficient circulating androgens. The prevalence of this condition is high (up to 50% of white males are affected by 50 years of age^[1-3]). AGA affects 80% of men and 50% of women, presenting two different patterns: a central and more diffuse in women (FAGA) and slightly different in men,

in which the main characteristic is the recession of the frontoparietal line (MAGA)^[2,3].

MAGA usually starts around the 20 years of age in men, affecting about 50% of the entire male population at 50 years of age and around 70% of men will eventually develop MAGA sometime in their lives^[2,4,5]. AGA is an androgenetic dependent illness, modulated by an active testosterone metabolite, called dihydrotestosterone (DHT)^[2,4,6-8]. Although the tissue distribution does vary, both enzyme 5 α -reductase types are found in the scalp follicles, which specifically concentrate in the dermal papilla^[2,9]. To pursue its effect, androgens bind to the human androgen receptor (AR), a member of the steroid-thyroid hormone receptor superfamily^[9]. Both testosterone and DHT can bind to the AR domain, which act as a transcription factor, regulating the expression of androgen-sensitive genes^[10]. The concentration of DHT, AR and 5 α -reductase has been demonstrated to be higher in the balding scalp^[11-14]. Moreover, evidence has shown that AGA has a polygenic mode of inheritance, after finding that 81.5% of balding sons had fathers with type 3 or more in the Hamilton-Norwood scale^[15], exceeding the autosomal dominant expectation of 50%. However, it has been difficult to encounter a gene related to AGA, since none were found in the Y chromosome neither the aromatase gene nor the 5 α -reductase^[16,17]. Moreover, it has been demonstrated that patients affected by AGA, especially those in early ages, perceive themselves older than they are, adding stress and considerable preoccupation to their lives. AGA truly becomes a psico-social problem for the patient becoming bald at a young age, who feels unattractive and less socially successful^[1,18-22].

At the present time, there are only two approved FDA treatments to deal with MAGA; oral Finasteride, which selectively inhibits the 5 α -reductase enzyme and reduces the concentration of DHT in the scalp follicle around 70%, inhibiting or even reducing the miniaturization of the hair follicle^[23-27], and topic Minoxidil, which action mechanism remains unclear^[3,27-30]. Even though both treatments are effective, they are not exempt of complications; the first and more importantly, they are both chronic treatments^[3,4]. For this reason, Finasteride over time can produce: depression, gynecomastia, hepatic enzymes elevation, cholesterol elevation, sexual dysfunction, impotence, decreased libido and mood disorder^[31]. On the other hand, the harmful effects of Minoxidil include: contact dermatitis, facial hypertrichosis and transitory hair loss^[3].

An enormous economic and human effort is being done trying to find new strategies and treatments for AGA, and a promising one is the Platelet-rich plasma (PRP)^[3,32]. PRP consists of an autologous preparation of concentrated plasma with a threefold to eightfold increase in platelet number, ~1.500.000/ μ L, compared to normal plasma^[33-35], which is extensively used to promote soft tissue healing. PRP started to be used in the 70s for its healing properties for cutaneous ulcers^[32]. Moreover, it has been utilized in other specialties like traumatology, plastic surgery and maxillofacial surgery. In dermatology its use is extended to pathologies like: cutaneous ulcers, alopecia areata, tensional alopecia, androgenetic alopecia, skin resurfacing, hair transplant and the scar treatment, to name a few^[36-40]. It is considered as a natural source of growth-factors (GFs)^[40], able to improve angiogenesis, stem cell recruitment^[33], remodel the extracellular matrix, together with effects of cellular proliferation and differentiation^[41]. The regenerative potential of PRP seems to depend on the levels of GFs liberated^[42,43]. A schematic representation of all platelets granules potentially released upon its activation are shown in Figure 1, for example growth factor (PDGF), transforming growth factor (TGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF), epidermal growth factor (EGF) or interleukin (IL)-1.

PRP is produced using different methods; open or closed technique (this very last one thanks to the disposable kits), in order to produce a platelet cocktail taken out from plasma^[45]. The PRP is initially obtained from 20 to 60mL of the patient's blood, followed by a centrifugation protocol in two stages. The first centrifugation separates the erythrocytes from the less heavy plasma, with a buffy coat in the interphase. The plasma and the buffy coat are aspirated and they are centrifuged at a high spin so that the platelets sediment. A plasma portion is eliminated and the platelet sediment is resuspended again with the remaining plasma^[46]. When treating AGA, PRP is injected subcutaneously, intradermal, or in the interfollicular alopecia area^[43,47]. A huge commercial offer exists to fabricate PRP^[34,47-49], however, a consensus protocol does not exist for the PRP preparation. In the literature we encounter preparation methods that differ from centrifugation, cellular and plasmatic proteins components, platelet activation, and site of injection^[50-56,57-63].

Anti-apoptotic effects of activated PRP have been suggested as one of the major contributing factors stimulating hair growth through the Bcl-2 protein and Akt signaling, prolonging dermal papilla cells survival during the hair cycle^[60]. TGF- β 1 is a known immune cellular system modulator and a cell growth regulator, which together with IGF-1 growth factor, stimulate cellular proliferation and inhibits apoptosis. In addition, the upregulation of FGF-7/b-catenin signaling pathways with the use of PRP suggest the stimulation of hair growth by inducing follicular stem cell differentiation^[50,64]. In addition, the release of VEGF and PDGF, known to have angiogenic properties, increase the perifollicular vascular network as previous studies have demonstrated^[57,58,60]. All of the platelet's growth factors have been reported to increase notably by the addition of the most used calcium chloride or the PRGF right before the PRP treatment application^[35,58].

In this literature review, all the studies published have been systematically analyzed in a unique revision that had the objective to evaluate PRP as a treatment for AGA, and to propose a clinical trial with a reliable PRP obtaining protocol, called the "Ultimate Platelet Rich-Plasma extraction protocol UPRP)".

METHODS

Numerous studies have been conducted lately to assess the efficacy of PRP as a hair restoration treatment option, but the question whether is effective for AGA or not remains unsolved. Thus, a systematic




Figure 1 Platelet components[44].

review in June 2017 has been conducted in order to gather all the evidence by searching through PubMed and Cochrane databases, using the keywords “Alopecia AND PRP”. This search resulted with a total of 38 articles, which we excluded 11 review articles, 6 studies using PRP to treat other hair diseases, 3 expert opinions, 2 articles were off topic, 1 abstract, and 1 article was conducted only with animals, resulting in a total of 14 studies. We focused on the most recent studies, especially those that included placebo-controlled trial. These 14 studies were carefully evaluated, focusing on the PRP protocol used and the results obtained in hair restoration, all summarized in three tables grouped by: study outcomes, PRP protocol, and PRP application. The first 10 article’s data were plotted to graphically show their hair restoration results.

SYSTEMATIC REVIEW

The latest study published by Alves and Grimalt in 2017 brought us an innovative approach on the AGA’s treatment, by combining PRP with minoxidil or finasteride. In this study, they recruited 25 patients with AGA, 11 males and 13 females, and treat all of them with PRP on one side of the head and saline solution on the other half-side, in combination of finasteride or minoxidil solution as ongoing treatment. After randomization, thirteen patients were treated with 1mL 5% minoxidil solution twice daily and 12 patients were medicated with 1 mg/day of oral finasteride, for a total of 25 patients.

Results were assessed by TrichoScan analysis at 3 and 6 months after the last treatment dosage, resulting in a statistically significant of mean hair count (hairs/0.65 cm²), hair density (1/cm²), and terminal hair density (1/cm²) in the PRP associated with medication group versus placebo after 6 months ($p < 0.05$; month 6 vs baseline, data not shown). The combination of PRP and 5% minoxidil group showed higher hair restoration than PRP and finasteride, resulting in an increase of the total hair count, total mean hair density, anagen and telogen percentages, and mean anagen/telogen ration ($p < 0.05$: PRP + minoxidil vs PRP + finasteride).

Biologically speaking, it makes sense to obtain a synergic effect by combining two therapies that potentiate both angiogenesis and hair buldge proliferation by two different mechanisms. Minoxidil and PRP together have shown higher restoration hair than the combination with Finasteride, opening new doors to AGA treatment in the future. However, we must take into account that the study was conducted with low grade alopecia in both men and women subjects recruited, and most of them were non-smokers, two aspects that may potentiate the therapeutic effects seen in this trial. As reported later on this review by Gentile *et al*, the effect of PRP therapy seems to decay over time, so future longer follow-up must be accomplished to see the most adequate therapy frequency.

Gentile *et al* also in 2017 made a very interesting approach to assess whether is important to activate the concentrated platelet plasma by comparing CPuntT Preparation System, a non-activated (A-PRP) system, to Arthrex Angel System or Regen Blood Cell Therapy, both being activated PRP (AA-PRP) systems. Proteins released from platelets were quantified before and after its activation with calcium, data shown in the following table.

Table 1 and figure 2 pretends to proof the non-similarity of secreted proteins with the C-PuntT system over the other two that needed previous activation. The amount of VEGF and PDGF-BB in the activated systems is significantly higher over the C-PunT system, and equal to the rest of parameters. IGF-1 was not measured with the C-PunT system that is why it is not represented.

This study shows an improvement in hair density with the C-PunT system of +64 ± 3 hairs/cm² after 3 months of treatment compared to

Table 1 Trichoscan analysis assessed by Alves and Grimalt.

| | Placebo | | PRP Treatment | |
|---|---------|-------|---------------|-------|
| | Mean | SD | Mean | SD |
| Hair Count (hairs/0.65 cm²) | | | | |
| Finasteride (n = 11) | 0.9 | 16.3 | 0.6 | 10.8 |
| 5% Minoxidil (n = 13) | 3.7 | 14.5 | 9.8 | 26.9 |
| p-value | 0.400 | | 0.011 | |
| Hair Density (1/cm²) | | | | |
| Finasteride (n = 11) | 1.4 | 25.1 | 1.8 | 16.7 |
| 5% Minoxidil (n = 13) | 5.1 | 23.9 | 12.3 | 34.2 |
| p-value | 0.283 | | 0.010 | |
| Terminal hair density (1/cm²) | | | | |
| Finasteride (n = 11) | -1.9 | 28.3 | 3.9 | 15.2 |
| 5% Minoxidil (n = 13) | 5.6 | 21.9 | 3.2 | 38.4 |
| p-value | 0.138 | | 0.175 | |
| Anagen Hair (%) | | | | |
| Finasteride (n = 11) | -2.1 | 15 | -2 | 12.2 |
| 5% Minoxidil (n = 13) | 1.5 | 13.8 | 5.5 | 19.7 |
| p-value | 0.078 | | 0.002 | |
| Telogen Hair (%) | | | | |
| Finasteride (n = 11) | 2.1 | 15 | 1.8 | 12.2 |
| 5% Minoxidil (n = 13) | -1.7 | 14 | -5.5 | 19.9 |
| p-value | 0.072 | | 0.002 | |
| Anagen/Telogen ratio(%) | | | | |
| Finasteride (n = 11) | -40.5 | 169.7 | -6.6 | 155.7 |
| 5% Minoxidil (n = 13) | 1.7 | 192.5 | 69.6 | 234 |
| p-value | 0.167 | | 0.018 | |

In bold p -value < 0.05 .




Figure 2 Hair density (hairs/cm²) (* p -value < 0.05)[65].

placebo and about +90 ± 6 hair/cm² with the Arthrex system after 6 months of treatment compared to baseline. On the other hand, the Regen system showed a reduction in hair density of -73 ± 24 hairs/cm² compared to baseline. The scalp histopathological examination under the microscope was conducted after two weeks of treatment with CPuntT system, which showed an increase of epidermal thickness, number of follicles, ki67+ expression, and capillary density assessed by CD31 expression over placebo.

They conducted an interesting study to approach whether platelets needed to be activated, but many questions remain unanswered. The scalp histopathological evaluation was only assessed in the A-PRP treatment group, leaving the AA-PRP group microscopic effects out of the picture. Also, the A-PRP was assessed at 3 months after treatment and the AA-PRP after 6 months, showing an inconsistent analysis between the treatment groups. Finally, the number of patients included in both groups was 3 times higher for the A-PRP group, leaving only 3 patients for each AA-PRP treatment group, and

placebo data was not shown in the AA-PRP group. The conclusion statement from Gentile *et al* was that PRP does not need to be activated because a greater increase in hair count and total hair density is found in the A-PRP group using the C-PunT system over the AA-PRP. Although that statement is true when comparing CPunT system to Regen, it is not suitable when looking at the group treated with the Arthrex system, as we can see in the following graph.

Anitua *et al* developed a pilot study in which the use of PRP resulted positive for hair follicle regeneration. To do so, they took 19 patients with AGA, 13 males and 6 females, and treat them with five injections of PRP at months 1, 2, 3, 4 and 7, previously activated by the addition of platelet rich growth factor (PRGF). Compared to baseline, all outcome measures demonstrated a positive result after 5 sessions of PRP injections, assessed at 12 months when compared to baseline. The growth factors released after centrifugation were quantified by ELISA from the supernatant, and the results are described in table 2 and the PDGF, TGFβ-1, and VEGF are graphed in figure 4 in order to visually compare to other articles' results.

Some of the results from Anitua *et al* are depicted in figure 5, where hair density, hair diameter and terminal/vellus hair are represented. We can see a statistically significant improvement ($p < 0.05$) in hair density, hair diameter and the ratio of terminal/vellus hair after 5 sessions of activated PRP at 12 months follow-up.

Histopathological examination also showed a statistically significant ($p < 0.05$) increase in epidermal thickness, basal keratinocytes proliferation (ki67+), perifollicular neoangiogenesis, and terminal/vellus hair ratio together with a decrease of the inflammatory perivascular infiltrate and an increase of bulge stem cell population after PRP treatment. On top of these objective positive results, 13 out of 19 patients referred to be satisfied with the results obtained.

Gupta *et al* conducted an open-labeled, not placebo-controlled pilot study with 30 male patients aged 20 to 50 years old. Each participant received 6 PRP treatments, administered 15 days apart, but their PRP treatment administration approach was unique from the other studies. After the scalp was activated by microneedling, PRP solution was massaged on the scalp. Hair density and diameter were measured at the vertex, 10cm from the glabella, by using TrichoScan

Table 2 Growth factors and cytokines concentrations.

| Protein | Collection System | A-PRP | Ca+2 AA-PRP |
|-----------------|-------------------|-----------|-------------|
| PDGF-BB (ng/mL) | Regen (AA-PRP) | 1.2 ± 0.3 | 4.0 ± 2 |
| | Athrex (AA-PRP) | 1.1 ± 0.6 | 3.0 ± 1 |
| | C-PunT (A-PRP) | 1.8 ± 0.4 | - |
| TGF-β1 (ng/mL) | Regen | 11 ± 2 | 15 ± 3 |
| | Athrex | 12 ± 1 | 13 ± 0 |
| IGF-1 (ng/mL) | Regen | 130 ± 20 | 140 ± 20 |
| | Athrex | 150 ± 40 | 150 ± 60 |
| VEGF (pg/mL) | Regen | 61 ± 20 | 210 ± 40 |
| | Athrex | 61 ± 20 | 260 ± 70 |
| | C-PunT | 100 ± 20 | - |
| FGF (pg/mL) | C-PunT | 280 ± 60 | - |

Table 3 Growth factors and cytokines concentrations.

| | Mean | SD |
|----------------|------|------|
| PDGF (ng/mL) | 33 | ±10 |
| TGFB-1 (ng/mL) | 21 | ±12 |
| VEGF (pg/mL) | 218 | ±127 |
| EGF (ng/mL) | 826 | ±221 |
| TSP-1 (µg/mL) | 268 | ±58 |
| Ang-1 (µg/mL) | 392 | ±122 |

Ang-1: angiotensin-1; EGF: epidermal growth factor; PDGF: platelet-derived growth factor; PRGF: plasma rich in growth factor; TGFβ1: transforming growth factor b1.

analysis, photographs analyzed by a blinded observer and self-assessment questionnaires. The results obtained showed an improvement of hair density and hair diameter detailed below, a $30.2 \pm 12\%$ average improvement in the photograph analysis, and a mean percentage improvement of 30 ± 13.1 on the basis of self-assessment evaluation. Interestingly enough, treatment response showed a higher efficacy in different clinical scenarios analyzed. Those with a lower grade of alopecia, subjects with shorter duration of disease before undergoing PRP therapy, and those subjects without a family history of alopecia benefit more from PRP therapy than the rest. The following tables summarize the results.

Alves and Grimalt conducted a randomized, placebo-controlled, double-blinded, half-headed clinical trial with 25 subjects. Subjects were grouped according to the half-head treated side; 3 mL of PRP on the right half of the head and 3mL of saline placebo on the left side. Results were assessed after three and six months, resulting in an increase of the mean anagen hair, mean telogen hair, hair density, and terminal hair density in PRP treated areas when compared with baseline. Mean total hair density at 3 and 6 months was the only result found to be statistically significant in the PRP treatment group when compared to placebo ($p < 0.05$).




Figure 3 Platelet growth factors (Log scale10). (*p-value>0.05)




Figure 4 Hair density (hairs/cm²). (**p-value <0.001)[57]




Figure 5 Platelet growth factors (Log Scale[10]).

Looking at the demographic characteristics of patients, treatment with PRP showed a statistically significant correlation between hair density and patients aged ≤ 40 years old, start hair loss ≥ 25 years old, a positive family history, and more than 10 years of AGA's appearance, when compared to placebo. This study also defends a positive correlation in PRP treated areas between anagen hairs (%) and patients aged more than 40 years old and beginning of AGA ≥ 25 years old, at 6 months.

Another similar randomized, placebo-controlled, double-blinded, half-headed clinical trial was done by Gentile *et al* with 23 male patients. PRP was injected in two out of four areas with apparent hair loss, and saline solution was injected into the other two remaining areas. The study found a statistically significant increase in many outcome measures; mean hair count, hair density and terminal hair density, after 3 months of PRP treatment compared to placebo. Specifically, a mean increase of 45.9 hairs/cm² in the treated area compared to 3.8 hairs/cm² in the placebo treated area after 3 months ($p < 0.0001$). The terminal hair density also improved significantly by 40.1 hairs/cm² with PRP over 5.6 hairs/cm² in the control area of the scalp ($p < 0.003$). Microscopic evaluation after 2 weeks from the last PRP treatment translated into a significant increase in the number of follicles, epidermal and hair follicular bulge cells, an increase of ki67+ basal keratinocytes, and an increase in small blood vessels around hair follicles in the treated skin area compared to baseline ($p < 0.05$).

The following table and graph summarizes the results obtained from this study.

At the microscopic evaluation after two weeks from the last PRP treatment, a statistically significant increase of epidermis thickness, number of follicles, ki67+ basal keratinocytes expression, and small blood vessels around hair follicles was demonstrated compared to placebo ($p < 0.05$). The clinical visual macroscopically effect of one patient's scalp treated with PRP is shown in the following image, demonstrating the potential therapeutic effect of activated PRP. However, 4 patients reported progressive hair loss around 16 months after the last PRP treatment.

Cervelli *et al* performed a very similar study to Gentile's with 10 men, and found similar positive results after 3 months of PRP treatment. All outcome measures showed statistically significant improvement ($p < 0.05$), compared to placebo. All data is represented in the following table and graph.

Microscopic analysis revealed that epidermal thickness, density of follicles, ki67+ expression, and hair follicle bulge cells were also increased compared to baseline ($p < 0.05$), suggesting an increase of keratinocyte and hair follicle proliferation as well as angiogenesis promotion by the PRP growth factors released during the treatment.

Singhal *et al* conducted a small not placebo-controlled study to check PRP treatment efficacy in 20 subjects; 8 males and 2 females, by using the Hair Pull test and photographs before and after treatment. Hair growth was observed in 6 subjects after just 7 days of treatment, and in 4 subjects after 15 days. By the end of the third month of PRP treatment, the Hair Pull test and the macroscopically evaluation showed superior outcomes, by showing a 65% reduction of hairs pulled and a higher hair density. No statistical analysis was reported on the observed data^[61].

On the other hand, there are two studies that have reported no improvement in hair repair after PRP treatment. Mapar *et al* conducted a single-blinded, randomized, placebo-controlled pilot study with 17 male subjects. They underwent a similar protocol to the one used by Alves and Grimalt, in which the same patient had their scalp divided in two square-shaped regions of 2.5 x 2.5 cm in size, at least 3 cm apart from each other and their corners were marked with a tattoo. A

Table 4 TrichoScope ASG analysis assessed by Anitua (In bold p -value < 0.05)

| | PRP Treatment | |
|---|---------------|----|
| | Mean | SD |
| Hair Density(follicles/cm²) | | |
| Baseline | 117 | 29 |
| 12 weeks | 156 | 36 |
| Hair Diameter (μm) | | |
| Baseline | 37 | 10 |
| 12 weeks | 55 | 9 |
| Terminal Hair Density (1/cm²) | | |
| Baseline | 48 | 17 |
| 12 weeks | 68 | 18 |
| Vellus Hair Density (1/cm²) | | |
| Baseline | 51 | 21 |
| 12 weeks | 32 | 17 |




Figure 6 Results at 12 months follow-up. (* p -value < 0.05) [58].

volume of 1.5 mL of saline solution and PRP treatment was injected in patients' scalp in 2 consecutive sessions, one month apart. Results were assessed after three and six months, showing no differences in terminal hair increase or vellus hair decrease between the PRP treated

areas compared to placebo neither compared to baseline in either group ($p > 0.05$).

Puig *et al* conducted a randomized, double blind, placebo-controlled trial with 26 women with female pattern hair loss. Women, at least 18 years old with a hair loss at a stage of Ludwig II, were randomized assigned into the PRP treatment or placebo group. Investigators marked a 4-cm² hair check data box in the central scalp at an exact distance from the glabella, where Cohen hair check system was used to analyze hair parameters. PRP was obtained from 60 mL of blood sample, using the non-activated Angel centrifuge system. Subjects either received a single 10 mL injection of PRP or normal saline solution at the previously marked area, and the results were analyzed after 26 weeks (4 months). No statistically significant differences were found in patient's hair count or hair mass between the PRP treatments and the control group ($p = 0.503$ and $p = 0.220$, respectively). However, 26.7% of patients treated with PRP reported coarser hair after treatment compared to a 18.2% in the placebo group, and 13.3% of the treated patients reported a substantial improvement in hair loss and hair thickness compared to a 0% in the placebo group^[63].

Tables 5, 6, 7 and 8 TrichoScan analysis, and subgroups analysis by alopecia grade, duration of alopecia, and family history assessed by Gupta.

| Hair Diameter (mm) | PRP Treatment | |
|--------------------------------------|--------------------------------------|--------------------|
| | Mean | SD |
| Baseline | 0.055 | 0.015 |
| 3 months | 0.072 | 0.017 |
| 6 month | 0.075 | 0.019 |
| % Change | 39.85 | 17.21 |
| Hair Density (1/10 mm ²) | Mean | SD |
| Baseline | 6.13 | 1.72 |
| 3 months | 7.67 | 1.88 |
| 6 month | 8.43 | 2.06 |
| % Change | 39.85 | 16.54 |
| 6 Months Increase (Mean ± SD) | | |
| Androgenetic Alopecia Grade | Hair Density (1/10 mm ²) | Hair Diameter (mm) |
| 3 | 3 ± 0 | 0.025 ± 0.007 |
| 4 | 3.5 ± 0.71 | 0.025 ± 0.007 |
| 5 | 2.33 ± 0.58 | 0.03 ± 0.01 |
| 6 | 1.73 ± 0.47 | 0.015 ± 0.007 |
| p-value | 0.044 | 0.019 |
| 6 Months Increase (Mean ± SD) | | |
| Duration of Alopecia | Hair Density (1/10 mm ²) | Hair Diameter (mm) |
| Up to 5 years | 2.68 ± 1 | 0.025 ± 0.007 |
| 6-10 years | 1.6 ± 0.52 | 0.025 ± 0.007 |
| > 10 years | 2.0 ± 0 | 0.03 ± 0.01 |
| p-value | 0.048 | 0.009 |
| 6 Months Increase (Mean ± SD) | | |
| Family History | Hair Density (1/10 mm ²) | Hair Diameter (mm) |
| Present | 2.15 ± 0.97 | 0.019 ± 0.007 |
| Absent | 3.25 ± 0.5 | 0.03 ± 0.008 |
| p-value | 0.011 | 0.027 |

The other older studies conducted by Schiavone *et al*, Takikawa *et al*, Khatu *et al*, and Gkini *et al* are summarized in Tables 1 to 3^[45,47,54,55].

PRP treatment has been consistently shown to be effective at the microscopic level, by measuring an increase in the epidermal thickness, basal keratinocytes proliferation (ki67+), and perifollicular neo-angiogenesis after 2 to 4 weeks after treatment. The question of how long this effect may last has not been checked by any of the studies analyzed, understanding the obvious inconvenience of the biopsy of the hair scalp for the patient. In order to approach the real effect of the PRP therapy compared to the biological effect from the wound itself made by the needle (recently proven to stimulate epidermal and hair follicle stem cells differentiation^[66]), we merged all the published data to date. We are aware of the differences encountered in the studies analyzed, and thus, we have only used hair density data from Trichoscan analysis and placebo-controlled trials, data shown in the following table.

Despite the differences from all the studies analyzed, PRP has shown a statistically significant difference when compared to placebo at 3 months, showing an increase of 30 hair follicles/cm². Thus, we can conclude that PRP seems a very promising therapy for AGA, and will bring patients better results once we have it standardized and maybe combined with other approved therapies, such as 5% minoxidil.

Future studies will need to be consistent with the PRP protocol used, use half-head system as placebo, include more patients, analyzed data with Trichoscan, gather the subjective benefit after treatment, and undergo a longer follow-up in order to assess the real efficacy of PRP and approach the best posology for this promising therapy.

DISCUSSION

Many dermatologists worldwide use PRP with the idea of helping patients affected by a hair loss problem, but the assessment of the real efficacy obtained with this treatment, either for the doctor or the patient, is not an easy task. The idea behind this article is to evaluate the different approximations to obtain PRP with scientific evidence, and develop a meticulous study method that will allow us to recognize what is the real effect of the PRP on treating AGA.

According to this review, there is not a consensus protocol in any of the studies reviewed. In many occasions, dermatologists apply what the manufacturer from the PRP isolation machinery suggests as the standard protocol. The exact concentration, dose, deepness of the dosage, frequency of injections or the number of PRP sessions needed to be effective in AGA differ significantly and are not always




Figure 7 Results at 12 months follow-up. (* p -value < 0.05)[59].

specified. However, some common steps exist between the studies analyzed to obtain PRP, which are detailed below.

*Platelet-Rich-Plasma Extraction Common Steps: (1) Peripheral blood is withdrawn from the same patient and transferred it into a tube with 3.8% sodium citrate. (2) The blood obtained is centrifuged at no more than 1.200 rpm. The centrifugation separates the sample into 3 visually recognizable layers; a top yellow layer (plasma), a thin layer in the middle called the buffy coat (white blood cells and platelets), and red blood cells (RBCs) in the bottom layer. (3) The plasma and the top part of the buffy coat (leukocytes rich) is discarded and the remaining buffy coat layer and a fraction of the RBCs are transferred into another tube. (4) Some authors undergo a second spin to achieve a more concentrated solution. (5) The upper ¾ of the supernatant is discarded from the tube. (6) The pellet obtained is ho-

mogenized with the remaining fluid and the PRP solution is finished. (6) In many cases, an activator such as calcium is added to the PRP in order to “activate” the platelets. (7) The PRP is injected with a 30-G needle into hair depleted areas.

A standardized method to evaluate the results obtained with the PRP does not exist either, very few patients are included in the studies described or the number between groups are not homogenous, and many others lack proper controls to evaluate results objectively. The main problem was the absence of a standardized, objective, reliable and no invasive method to evaluate AGA’s hair loss, as well as the results after using PRP treatment. For these numerous reasons, we would like to propose a methodology for future studies, so that the effectiveness of PRP in AGA can be assessed properly and recommend patients PRP treatment with proper clinical evidence.




Figure 8 Results at 12 months follow-up. (**p*-value < 0.05)[35].




Figure 13 Blood Components[64].

Table 9 Trichoscan analysis assessed by Alves and Grimalt.

| | Placebo | | | PRP Treatment | | | Placebo vs PRP |
|-------------------------------|---------|-------|-----------------|---------------|-------|-----------------|-----------------|
| | Mean | SD | <i>p</i> -value | Mean | SD | <i>p</i> -value | <i>p</i> -value |
| Anagen Hair (%) | | | | | | | |
| Baseline | 62.1 | 17.4 | > 0.05 | 62.1 | 16.1 | > 0.05 | > 0.05 |
| 3 months | 63.5 | 18.9 | > 0.05 | 67.9 | 13.8 | < 0.05 | > 0.05 |
| 6 month | 66.3 | 15.9 | < 0.05 | 67.6 | 13.1 | < 0.05 | > 0.05 |
| Telogen Hair (%) | Mean | SD | <i>p</i> -value | Mean | SD | <i>p</i> -value | <i>p</i> -value |
| Baseline | 37.9 | 17.4 | > 0.05 | 37.9 | 16.1 | > 0.05 | > 0.05 |
| 3 months | 34.5 | 16.5 | > 0.05 | 35.8 | 14.4 | < 0.05 | > 0.05 |
| 6 month | 33.7 | 15.9 | < 0.05 | 32.4 | 13.1 | < 0.05 | > 0.05 |
| Anagen/Telogen ratio(%) | Mean | SD | <i>p</i> -value | Mean | SD | <i>p</i> -value | <i>p</i> -value |
| Baseline | 137.5 | 209.5 | > 0.05 | 128.4 | 174.8 | > 0.05 | > 0.05 |
| 3 months | 159.1 | 210.1 | > 0.05 | 185.7 | 199.9 | < 0.05 | > 0.05 |
| 6 month | 148.2 | 173.1 | > 0.05 | 156 | 164.3 | < 0.05 | > 0.05 |
| Hair Density (1/cm²) | Mean | SD | <i>p</i> -value | Mean | SD | <i>p</i> -value | <i>p</i> -value |
| Baseline | 167.8 | 51.2 | > 0.05 | 167.1 | 55.6 | > 0.05 | > 0.05 |
| 3 months | 167.1 | 51.3 | > 0.05 | 181.9 | 63.6 | < 0.05 | < 0.05 |
| 6 month | 165.7 | 55.2 | > 0.05 | 179.9 | 62.7 | < 0.05 | < 0.05 |
| Terminal hair density (1/cm²) | Mean | SD | <i>p</i> -value | Mean | SD | <i>p</i> -value | <i>p</i> -value |
| Baseline | 160 | 48.9 | > 0.05 | 159.9 | 55.1 | > 0.05 | > 0.05 |
| 3 months | 161.9 | 52.2 | > 0.05 | 168.2 | 60.7 | > 0.05 | > 0.05 |
| 6 month | 161.9 | 52.2 | > 0.05 | 165.8 | 56.8 | < 0.05 | > 0.05 |
| Hair Count (hairs/0.65 cm²) | Mean | SD | <i>p</i> -value | Mean | SD | <i>p</i> -value | <i>p</i> -value |
| Baseline | 111 | 33.9 | > 0.05 | 110.8 | 37.6 | > 0.05 | > 0.05 |
| 3 months | 112 | 35.7 | > 0.05 | 115 | 41.8 | > 0.05 | > 0.05 |
| 6 month | 112.7 | 34.9 | > 0.05 | 113.2 | 39.4 | > 0.05 | > 0.05 |

In bold *p*-value < 0.05.




Figure 9 Results at 14 months follow-up. (***) p -value < 0.0001[60].




Figure 10 Results at 12 months follow-up. (***) p -value < 0.0001[51].




Figure 11 Results at 3 and 6 months follow-up (p -value > 0.05)[62].




Figure 12 Results merged at 3 months follow-up (* p -value < 0.05).

Table 10 Trichoscan analysis assessed by Gentile.

| | Placebo | | PRP Treatment | |
|-------------------------------|---------|------|---------------|------|
| | Mean | SD | Mean | SD |
| Hair Count | | | | |
| Baseline | 91.1 | 22.4 | 87.9 | 20.5 |
| 14 weeks | 89.6 | 20.9 | 123.2 | 33.7 |
| Hair Density (follicles/cm²) | Mean | SD | Mean | SD |
| Baseline | 166.5 | 45.6 | 161.2 | 41.9 |
| 14 weeks | 170.3 | 42.1 | 207 | 56.3 |
| Terminal Hair Density (1/cm²) | Mean | SD | Mean | SD |
| Baseline | 154.5 | 40.4 | 149.1 | 43.1 |
| 14 weeks | 148.9 | 41.1 | 189.2 | 46.6 |
| Vellus Hair Density (1/cm²) | Mean | SD | Mean | SD |
| Baseline | 16.9 | 11.6 | 16.6 | 8.9 |
| 14 weeks | 17.9 | 13.8 | 18.5 | 8.7 |

In bold p -value < 0.0001.

Table 11 Trichoscan analysis assessed by Cerevelli.

| | Placebo | | PRP Treatment | |
|-------------------------------|---------|------|---------------|------|
| | Mean | SD | Mean | SD |
| Hair Count (units) | | | | |
| Baseline | 111.3 | 28.9 | 103.6 | 30.9 |
| 12 weeks | 109.3 | 28.2 | 121.6 | 34.1 |
| Hair Density (follicles/cm²) | Mean | SD | Mean | SD |
| Baseline | 171.2 | 44.4 | 159.4 | 47.6 |
| 12 weeks | 168.1 | 43.3 | 187.1 | 52.5 |
| Terminal Hair Density (1/cm²) | Mean | SD | Mean | SD |
| Baseline | 152.7 | 39.7 | 142.7 | 41.8 |
| 12 weeks | 150.6 | 41.7 | 169.8 | 47 |
| Vellus Hair Density (1/cm²) | Mean | SD | Mean | SD |
| Baseline | 16.9 | 10.4 | 14.8 | 9.7 |
| 12 weeks | 17.4 | 13.9 | 15.8 | 8.5 |

In bold p -value < 0.0001.

Table 12 Magnifying glass analysis assessed by Mapar.

| | Placebo | PRP Treatment |
|-------------------------------|---------|---------------|
| | Mean | Mean |
| Terminal Hair Density (1/cm²) | | |
| Baseline | 92 | 87.29 |
| 3 months | 91.65 | 84.65 |
| 6 months | 91.76 | 85.06 |
| Vellus Hair Density (1/cm²) | Mean | Mean |
| Baseline | 41.82 | 43.35 |
| 3 months | 40.32 | 42.82 |
| 6 months | 40.18 | 41.76 |

p -value > 0.05.

Table 13 Average hair density from placebo-controlled trials.

| | Hair Density (follicles/cm²) | Placebo | | PRP Treatment | |
|------------------------|------------------------------|---------|------|---------------|------|
| | | Mean | SD | Mean | SD |
| Alves and Grimalt 2017 | Baseline | 150.8 | 46.1 | 149.5 | 42 |
| | 3 months | 153.3 | 42.2 | 160.5 | 47.1 |
| Alves and Grimalt 2016 | Baseline | 167.8 | 51.2 | 167.1 | 55.6 |
| | 3 months | 167.1 | 51.3 | 181.9 | 63.6 |
| Gentile 2017 (A-PRP) | Baseline | 225 | 15 | 218 | 17 |
| | 3 months | 227 | 16 | 282 | 20 |
| Gentile 2015 | Baseline | 166.5 | 45.6 | 161.2 | 41.9 |
| | 3 months | 170.3 | 42.1 | 207 | 56.3 |
| Cerevelli 2014 | Baseline | 171.2 | 44.4 | 159.4 | 47.6 |
| | 3 months | 168.1 | 43.3 | 187.1 | 52.5 |
| Average | | Mean | SEM | Mean | SEM |
| | Baseline | 176.26 | 12.6 | 171.04 | 12.1 |
| | 3 months | 177.16 | 12.8 | 203.7 | 20.9 |

Results from Trichoscan analysis (In bold p -value < 0.05).

Supplementary table 1 Study outcomes.

| Study | Study Design | | | | n (M/F) ♂: Norwood Class ♀: Ludwig Class | Treatment Outcomes Measured ($p < 0.05$) | | | | | | | | Adverse Effects | Subjective Assessment | Objective Assessment |
|-----------------------------|--------------------|------------|---------|-----------|--|--|--------------------|--------------------|---|--|--------------------------|--|---------------------------------|---|--|---|
| | Placebo Controlled | Randomized | Blinded | Half-head | | Hair density (follicles/cm ²) | Hair Diameter (µm) | Hair Count (units) | Anagen Hairs (%) or Terminal (hairs/cm ²) | Telogen Hairs (%) or Vellus (hairs/cm ²) | Epidermal Thickness (µm) | New Blood Vessels (1/mm ²) | Ki67 + (cells/mm ²) | | | |
| 1. Alves and Grimalt (2017) | Y | Y | Y | Y | 24 (11/13) Aged ♂:II-V ♀:I-III | Y | - | Y | Y* | Y* | - | - | - | Not present. | Not described. | Not described. |
| 2. Gentile et al (2017) | Y | Y | Y (3) | N | 24 (24/0) Aged 19-63 ♂: II-IV | Y | - | Y | Y | Y | Y | Y | Y | Not described. | Not described. | Not described. |
| 3. Anitua et al. (2017) | N | N | Y (1) | N | 19 (13/6) Aged 27-60 ♂: III-VI ♀: II | Y | Y | Y | Y | Y | Y | Y | Y | Erythema and local edema, not present after 24 hours. | Likert scale from patients: 7 very satisfied, 6 satisfied, 5 indifferent, 1 unsatisfied, 0=very unsatisfied. | Clinical evaluation before and after 12 months of treatment were scored in a 3 category scale: 0 (masked evaluators found no differences) -1 (if they failed to recognize each image) +1 (if the masked evaluators succeeded in recognizing each image) |
| 4. Alves and Grimalt (2016) | Y | Y | Y(2) | Y | 25 (12/13) Aged 18-65 ♂: II-V ♀: I-III | Y* | N | N | N | N | - | - | - | Local injection pain. | Not described. | Not described. |
| 5. Gentile et al. (2015) | Y | Y | Y (1) | Y | 23(23/0) Aged 19-63 ♂: IIa-IV | Y | - | Y | Y | Y | Y | Y | Y | Not present. | Physician's and patient's global assessment scale, results not reported. | |
| 6. Cerevelli et al (2014) | Y | Y | Y | Y | 10 (10/0) Aged 20 to 52 ♂: IIa-IV | Y | - | Y | Y | - | Y | Y | Y | Not present. | Physician's and patient's global assessment scale, results not reported. | |
| 7. Shingai et al (2016) | N | N | N | N | 10 (8/2) Aged 25-35 ♂: I-IV ♀: I-II | Y | - | Y | - | - | - | - | - | Mild headache. No inflammation nor infection. | Not described. | Not described. |
| 8. Puig et al (2016) | Y | Y | Y | N | 26 (0/26) ♀:II | - | - | Y | - | - | - | - | - | | Not described. | |
| 9. Mapar et al (2016) | Y | Y | Y (1) | Y | 17(17/0) Aged 24-45 ♂:IV-VI | - | - | - | Y | Y | - | - | - | Not present. | Not described. | Not described. |

| | | | | | | | | | | | | | | | | |
|----------------------------|---|---|---|---|---|---|---|---|---|---|---|---|---|--------------|--|------------------------|
| 10. Puig et al (2016) | Y | Y | Y | N | 26 (0/26) >18 years old ♀:II | - | - | Y | - | - | - | - | - | Not present. | 13,3% of the treatment subjects claimed to have experienced substantial improvement in hair loss, rate of hair loss, and hair thickness. | Not described. |
| 11. Schiavone et al (2014) | N | - | N | N | 64 (42/22) Aged 28-32 ♂:II-V ♀:I-II | - | Y | Y | - | - | - | - | - | Not present. | Not described. | Not described. |
| 12. Gkini et al(2014) | N | N | N | N | 20 (18/2) Aged 24-72 ♂:II-Va ♀:I | Y | - | - | - | - | - | - | - | Not present. | Patient Self-assessment Questionnaire | Not described. |
| 13. Khatu et al (2014) | N | N | N | N | 11 (11/0) Aged 20-40 ♂:II-IV | - | - | Y | - | - | - | - | - | Not present. | Patient Self-assessment Questionnaire | Not described. |
| 14. Takikawa et al (2011) | Y | - | N | Y | 26 (16/10) Aged 28-59 Thin hair | - | - | Y | - | - | Y | Y | - | Not present. | Not described. | No+A12:Q16t described. |

No placebo-controlled studies are compared to baseline, if they use placebo, they are compared to placebo.

Numbers 1,2,3 means single-blinded (1), double-blinded (2), triple-blinded (3).

1. *Only in the combination of PRP + Minoxidil

2. AP results from A-PRP only. Hair density and hair count results from Arthrex compared to baselines and C-PunT system compared to placebo.

5. Differences Alves at 3 and 6 months. Y* <40 years and AGA >25 and N* Age>40 and AGA>25 when compared to placebo.

Supplementary table 2 PRP protocol

| Study | Blood Volume (mL) | Activators | Force (g) | Time (min) | Force (g) | Time (min) | Platelet Enrichment (PRP/Plasma) | Other Details |
|-----------------------------|--|---|-----------|------------|---------------|------------|---|--|
| 1. Alves and Grimalt (2017) | 20 | 0.15mL of 10% Calcium chloride | 460 | 8 | Not performed | - | 3 | 3/4 of the supernatant is discarded (platelet-poor-plasma, PPP) and the resulting solution is used as PRP. Hair count (# of hairs/0,65 cm ²) |
| 2. Gentile et al. (2017) | a. 55 b. 24 c. 120 | a. None b and c. 10% calcium gluconate | 1200 rpm | 10 | Not performed | - | 5 | The top 2mL after centrifugation were discarded. > 40 µm included as terminal hairs. Results not shown. |
| 3. Anitua et al. (2017) | 18 | PRGF (BTI Biotechnology Institute) | 580 | 8 | Not performed | - | 2.08 | 2 cm ³ platelet-rich plasma was gathered, right above the leukocyte buffy coat. 40-60 µm is thin hair >80 µm thick hair |
| 4. Gupta et al (2017) | - | - | - | - | - | - | Not Reported | |
| 5. Alves and Grimalt (2016) | 20 | 0.15mL of 10% Calcium chloride | 460 | 8 | Not performed | - | 3 | 3/4 of the supernatant is discarded (platelet-poor-plasma, PPP) and the resulting solution is used as PRP. Hair count (# of hairs/0.65 cm ²) |
| 6. Gentile et al.(2015) | a. 18mL b. 60mL | Ca+2 | 1100 rpm | 10 | 1200 rpm | 10 | About 5 (1.48M platelets) | Two-step centrifugation to obtain a platelet pellet that may include leukocytes, a was activated with calcium and b selected by the CPunT system with a light selector. > 40 µm terminal hairs |
| 7. Cerevelli et al (2014) | 18 cc | Ca+2 | 1100 | 10 | Not performed | - | Not Reported | |
| 8. Shingal et al (2016) | 20 mL | 10 % Calcium chloride | 1500 rpm | 6 | 2500 rpm | 15 | Not Reported | Intermediate PRP rich layer (5% of total volume) was collected with a Finn pipette in another test tube. After the second centrifugation, the PRP poor top layer was discarded. |
| 9. Mapar et al (2016) | 9 ml (Plus 1mL of acidic citrate dextrose) | Calcium gluconate (0.1ml per mL of PRP) | 3000 rpm | 6 | 3300 | 3 | X 3 | |
| 10. Puig et al (2016) | 60 ml | No | - | - | - | - | X 2.75 - 3.4 | Angel system for PRP obtention |
| 11. Schiavone et al (2014) | a. 60 mL b. 40 mL | No (Scalproller used to favor platelet activation) | - | - | - | - | a. X 6-7 b. X 4 with addition of plasmatic protein concentrate | |
| 12. Gkini et al(2014) | 16 ml | Calcium gluconate (0.1 mL per 0.9 ml of PRP; 1:9 ratio) | 1500 x g | 5 | 1500 | 5 min | x 5.8 | |
| 13. Khatu et al (2014) | 20 ml | Calcium chloride (1:9 ratio) | 1500 rpm | 6 | 2500 rpm | 15 | Not Reported | |
| 14. Takikawa et al (2011) | 20 ml | - | 1700 rpm | 15 | 3000 rpm | 5 | Not Reported | |

METHODS PROPOSAL

We believe that a randomized, placebo-controlled, double-blinded, half-head study would be the best way to objectively assess the real efficacy of PRP. To better clarify the use of PRP activation, we propose to undergo a two-arm study; in which half of the patients will be randomized into a group receiving either activated PRP with calcium and saline solution in the other half of the head, and the other half will receive PRP without being activated and saline solution in the other half. Only by comparing the micro-trauma done by the injection of saline solution, we will be able to determine whether the therapeutic effects come from the “needle effect” or the PRP itself. All data will need to be processed by Trichoscan analysis, photographs and subjective questionnaires before and after treatment. The other question that remains unanswered is whether the PRP activation is necessary and which technology and protocol steps we need to do

to obtain the best quality PRP. A longer follow-up, about 18 months after stopping the treatment, may be of interest in order to discover how long the effect of the PRP therapy lasts^[60].

From our own experience, mixed together with recent evidence from this systematic review, we propose the following protocol that might change in the future if new scientific evidence demonstrated other results.

STATEMENT OF ETHICS

We ensure the quality and integrity of our work, in which the entire scientific literature has been analyzed thoroughly and all the papers studying PRP’s efficacy were considered in the same manner. No patients were used to write this paper, and thus, no informed consent or money of any sort was needed to conduct this research.

Supplementary table 3 PRP application.

| Study | PRP Volume Injection | PRP treatments | Intervals b/w treatments | Follow-up | PRP Application |
|-----------------------------|---|----------------|---|--|--|
| 1. Alves and Grimalt (2017) | 4mL | | | 3 and 6 Months | Injected intradermally into 4 selected areas (2 frontal and 2 occipital, marked with a central dot tattoo), at 0.15 to 0.20 mL/cm ² using a 30 G needle. No anesthesia used. Placebo: 4mL of saline solution at the other half-head |
| 2. Gentile et al. (2017) | a. 9mL b. 9mL c. 8mL | 3 | 1 Month | a. 3 Months b/c. 6 Months | a. Injected intradermally at 5mm depth using a Ultim Gun into 4 selected areas (frontal, parietal, vertex, and occipital), cleansed with 70% alcohol, at 0.2 mL/cm ² using 30G needles. No anesthesia used. Placebo: Saline solution at the region not treated (control). Example: Frontal vs parietal or parietal vs vertex (PRP vs placebo). Same number of injections were made in each group. b. Same as above with a Luer-lock syringe with 25G needle. |
| 3. Anitua et al (2017) | 3 to 4 mL | 5 | 1 Month (booster at 7 months after the start point) | 12 Months | 3 to 4 cm ³ of freshly activated PRGF was injected intradermally into the hair-depleted areas of the patient's scalp using 30 G needles. For men: 3 transitional areas of hair loss were defined for the phototrichogram analysis: intersection at 12 cm from the left/right eyebrow and 10 cm from the left/right ear, respectively, and 15 cm from the forehead (vertex area). For women, 3 aligned transitional areas involving mild scalp and crown region were defined. |
| 4. Gupta et al (2017) | - | 6 | 15 days | 6 months | Scalp was activated by microneedling, then PRP was massaged into the vertex of the scalp (10cm from the glabella). |
| 5. Alves and Grimalt (2016) | 3mL | 3 | 1 Month | 3 and 6 Months | Injected intradermally into 4 selected areas (2 frontal and 2 occipital, marked with a tattoo), at 0.15 mL/cm ² using a 30G needle. No anesthesia used. Placebo: 3mL of saline solution at the other half-head |
| 6. Gentile et al. (2015) | a. 9mL b. 20mL-->9mL (CPunT) | 3 | 1 Month | 2 Years (Baseline, 2, 6, 12, 16, and 24 months post first treatment) | Injected inderfollicularly using Luer-lock syringe within 2 of the 4 selected areas of the scalp (physiological solution into the other 2 areas) after the scalp was cleansed with 70% alcohol, at 0.1mL/cm ² using 30G needles. No anesthesia was used. |
| 7. Cerevelli et al (2014) | 9mL | 3 | 1 Month | 12 Months (Baseline, 14 weeks, 6 months, and 12 months) | Intradermal injections at 0.1mL/cm ² into two of the 4 selected halves (frontal or parietal), placebo was injected into the other 2 halves after the scalp was cleansed with 70% alcohol. Local anesthesia was not used. |
| 8. Shingal et al (2016) | 8-12mL | 4 | 2 weeks | 3 Months | Injections using nappage technique (multiple small injections in linear pattern 1cm apart) with an insulin syringe, after area was cleansed with ethanol and povidone-iodine |
| 9. Mapar et al (2016) | 1.5 ml | 2 | 1 month | 6 months (at 1,3 and 6 months post initial treatment) | Injections (1.5mL of PRP) within one of two 2.5cm x 2.5cm square regions, at least 3cm apart, in the scalp randomly assigned to be a case square (control square received 1.5 mL of normal saline). Randomization of case and control squares was performed using a random number table. Iron oxide and titanium dioxide containing substances were used to tattoo the corners of the squares. |
| 10. Puig et al (2016) | 10 ml | 1 | N/a | 26 weeks (at 4 week intervals) | Single subcutaneous injection within the 4 cm ² area in the central scalp (termed the "hair check data box"), after anesthesia (2% lidocaine and 0.5% bupivacaine) was administered |
| 11. Schiavone et al (2014) | a. 6-8 mL PRP + 3-4 mL of plasmatic protein concentrate= 9-12mL; 0.2-0.3 mL per injection b. same as above | 2 | 3 months | 6 months | After local anesthesia (xylocaine 1%, with adrenaline 1:100,000) was administered, cutaneous inflammation was induced via application of gentle pressure using 1.0mm deep Scalproller to favor activation of injected platelets. Then, superficial injections were administered 1cm apart. |
| 12. Gkini et al(2014) | 6 ml (0.05-0.1 mL/cm ²) | 3 (+1booster) | 21 days (booster 6 months after onset) | 1 year | Injections (0.05-0.1mL/cm ²) were performed using nappage technique in affected areas to a depth of 1.5-2.5 mm. A specific area was checked at all times by defining a 'V' (Kang's point) as proposed by Lee. |
| 13. Khatu et al (2014) | 2 - 3 ml | 4 | 2 weeks | 12 weeks | Nappage technique injections (2-3 cc) into a prefixed 1cm squared area over the right parietal area. Anesthetic cream was applied before each treatment after cleaning the skin with cetavlon, spirit and povidone-iodine. |
| 14. Takikawa et al (2011) | 3 ml | 5 | 2-3 weeks | 12 weeks | Subcutaneous injection (3mL) into selected 1cm x 1cm areas measured from the nasal tip and upper part of the auricular base. |

DISCLOSURE STATEMENT

In accordance with Universitat Internacional de Catalunya policies and procedures, and our ethical obligation as researchers, we are reporting that we do not have financial and/or business interests that may be affected by the research reported in the enclosed paper.

Our interest in this publication is to bring a new perspective into the PRP's efficacy, in order to call for a more solid evidence before extending the use of PRP into our patients.

REFERENCES

1. Han SH, Byun JW, Lee WS, Kang H, Kye YC, Kim KH, Kim

- DW, Kim MB, Kim SJ, Kim HO, Sim WY, Yoon TY, Huh CH, Hwang SS, Ro BI, Choi GS. Quality of life assessment in male patients with androgenetic alopecia: result of a prospective, multicenter study. *Ann Dermatol.* 2012 Aug; **24(3)**: 311-8. [PMID: 22879715]; [DOI: 10.5021/ad.2012.24.3.311].
2. Ellis JA, Sinclair R, Harrap SB. Androgenetic alopecia: pathogenesis and potential for therapy. *Expert Rev Mol Med.* 2002 Nov 19; **4(22)**: 1-11. [PMID: 14585162]; [DOI: 10.1017/S1462399402005112].
 3. Varoithai S, Bergfeld WF. Androgenetic Alopecia: An Evidence-Based treatment Update. *Am J Clin Dermatol.* 2014 Jul; **15(3)**: 217-30. [PMID: 24848508]; [DOI: 10.1007/s40257-014-0077-5].
 4. Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia. A systematic review. *Arch Dermatol.* 2010 Oct; **146(10)**: 1141-50. [PMID: 20956649]; [DOI: 10.1001/archdermatol.2010.256].
 5. Rhodes T, Girman CJ, Savin RC, Kaufman KD, Guo S, Lilly FR, Siervogel RM, Chumlea WC. Prevalence of male pattern hair loss in 18-49 year old men. *Dermatol Surg.* 1998 Dec; **24(12)**: 1330-2. [PMID: 9865198]; [DOI: 10.1111/j.1524-4725.1998.tb00009.x].
 6. Trüeb RM. Molecular mechanisms of androgenetic alopecia. *Exp Gerontol.* 2002 Aug-Sep; **37(8-9)**: 981-90. [PMID: 12213548]; [DOI: 10.1016/S0531-5565(02)00093-1].
 7. Inui S, Itami S. Molecular basis of androgenetic alopecia: from androgen to paracrine mediators through dermal papilla. *J Dermatol Sci.* 2011 Jan; **61(1)**: 1-6. [PMID: 21167691]; [DOI: 10.1016/j.jdermsci.2010.10.015].
 8. Zhuo FL, Xu W, Wang L, Wu Y, Xu ZL, Zhao JY. Androgen receptor gene polymorphisms and risk for androgenetic alopecia: a meta-analysis. *Clin Exp Dermatol.* 2012 Mar; **37(2)**: 104-11. [PMID: 21981665]; [DOI: 10.1111/j.1365-2230.2011.04186.x].
 9. Eicheler W, Happle R, Hoffman R. 5 alpha-reductase activity in the human hair follicle concentrates in the dermal papilla. *Arch Dermatol Res.* 1998 Mar; **290(3)**: 126-132. [PMID: 9558487]; [DOI: 10.1007/s004030050277].
 10. Janne, O.A., Palvimo JJ, Kallio P, Mehto M. Androgen receptor and mechanism of androgen action. *Ann Med.* 1999; **25**, 83-89. [PMID: 8435194]; [DOI: 10.3109/07853899309147863].
 11. Hamilton, J.B. Male hormone stimulation is a prerequisite and an incitant in common baldness. *Am J Anat.* 1942; **71**, 451-480; [DOI: 10.1002/aja.1000710306].
 12. Griffin, J.E. and Wilson, J.D (1989). The resistance syndromes: 5alpha-reductase deficiency, testicular feminisation and related disorders. In *The Metabolic Basis of Inherited Disease*: 1919-1944. McGraw Hill: New York, USA. [DOI: 10.1036/ombid.192].
 13. Imperato-McGinley, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. *Science* 1974; **186**: 1213-1215. [PMID: 4432067]; [DOI: 10.1126/science.186.4170.1213].
 14. Schweikert, H.U. and Wilson, J.D. Regulation of human hair growth by steroid hormones. II. Androstenedione metabolism in isolated hairs. *J Clin Endocrinol Metab* 1974; **39**: 1012-1019. [PMID: 4823922]; [DOI: 10.1210/jcem-38-5-811].
 15. Ellis, J.A, Stebbing, M. and Harrap, S.B. Genetic analysis of male pattern baldness and the 5alpha-reductase genes. *J Invest Dermatol.* 1998; **110**: 849-853. [PMID: 9620288]; [DOI: 10.1046/j.1523-1747.1998.00224.x].
 16. Ellis, J.A. and Harrap, S.B. The genetics of androgenetic alopecia. *Clin Dermatol.* 2001; **19**: 149-154. [PMID: 11397593]; [DOI: 10.1016/S0738-081X(00)00125-5].
 17. Ellis, J.A, Stebbing, M. and Harrap, S.B. Polymorphism of the androgen receptor gene is associated with male pattern baldness. *J Invest Dermatol.* 2001; **116**: 452-455. [PMID: 11231320]; [DOI: 10.1046/j.1523-1747.2001.01261.x].
 18. Tabolli S, Sampogna F, di Pietro C, Mannooranparampil TJ, Ribuffo M, Abeni D. Health status, coping strategies, and alexithymia in subjects with androgenetic alopecia: a questionnaire study. *Am J Clin Dermatol.* 2013 Apr; **14(2)**: 139-45. [PMID: 23413102]; [DOI: 10.1007/s40257-013-0010-3].
 19. Sampogna F, Tabolli S, Abeni D. Impact of different skin conditions on quality of life. *G Ital Dermatol Venereol.* 2013 Jun; **148(3)**: 255-61. [PMID: 23670062].
 20. Budd D, Himmelberger D, Rhodes T, Cash TE, Girman CJ. The effects of hair loss in European men: a survey in four countries. *Eur J Dermatol.* 2000 Mar; **10(2)**: 122-7. [PMID: 10694311].
 21. Cash TF. The psychological effects of androgenetic alopecia in men. *J Am Acad Dermatol.* 1992 Jun; **26(6)**: 926-31. [PMID: 1607410]; [DOI: 10.1016/0190-9622(92)70134-2].
 22. Girman CJ, Rhodes T, Lilly FR, *et al* Effects of self-perceived hair loss in a community sample of men. *Dermatology.* 1998; **197(3)**: 223-9. [PMID: 9812025]; [DOI: 10.1159/000018001].
 23. Rittmaster RS. Finasteride. *N Engl J Med.* 1994 Jan 13; **330(2)**: 120-5. [PMID 7505051]; [DOI: 10.1056/NEJM199401133300208].
 24. Drake L, Hordinsky M, Fiedler V, *et al* The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. *J Am Acad Dermatol.* 1999 Oct; **41(4)**: 550-4. [PMID: 10495374]; [DOI: 10.1016/S0190-9622(99)70295-1].
 25. Whiting DA, Waldstreicher J, Sanchez M, Kaufman KD. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of erial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women. *J Invest Dermatol Symp Proc.* 1999 Dec; **4(3)**: 282-4. [PMID: 10674382]; [DOI: 10.1046/j.1365-2133.1999.03042.x].
 26. Bayne EK, Flanagan J, Einstein M, *et al* Immunohistochemical localization of types 1 and 2 5alpha-reductase in human scalp. *Br J Dermatol.* 1999 Sep; **141(3)**: 481-91. [PMID: 10583052]; [DOI: 10.1046/j.1365-2133.1999.03042.x].
 27. Blumeyer A, Tosti A, Messenger A, *et al* European Dermatology Forum (EDF). Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. *J Dtsch Dermatol Ges.* 2011 Oct; **9 Suppl 6**: S1-S7. [PMID: 21980982]; [DOI: 10.1111/j.1610-0379.2011.07802.x].
 28. Van Zuuren EJ, Fedorowicz Z, Carter B. Evidence-based treatments for female pattern hair loss: a summary of a Cochrane systematic review. *Br J Dermatol.* 2012 Nov; **167(5)**: 995-1010. [PMID: 23039053]; [DOI: 10.1111/j.1365-2133.2012.11166.x].
 29. Van Zuuren EJ, Fedorowicz Z, Carter B, Andriolo RB, Schoones J. Interventions for female pattern hair loss. *Cochrane Database Syst Rev.* 2012 May 16; **5**. [PMID: 22592723]; [DOI: 10.1002/14651858.CD007628.pub3].
 30. Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, Zhang P, Kohut B. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. *J Am Acad Dermatol.* 2007 Nov; **57(5)**: 767-74. [PMID: 17761356]; [DOI: 10.1016/j.jaad.2007.04.012].
 31. Belknap SM, Aslam I, Kiguradze T, Temps WH2, Yarnold PR3, Cashy J4, Brannigan RE5, Micali G6, Nardone B2, West DP. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenetic Alopecia. A Meta-analysis. *JAMA Dermatol.* 2015 Jun; **151(6)**: 600-6. [PMID: 25830296]; [DOI: 10.1001/jamadermatol.2015.36].
 32. Pierce GF, Mustoe TA, Lingelbach J, Masakowski VR, Griffin GL, Senior RM, Deuel TF. Platelet-derived growth factor and transforming growth factor-beta enhance tissue repair activities by unique mechanisms. *J Cell Biol.* 1989; **109**: 429-40. [PMID: 2745556]; [DOI: 10.1083/jcb.109.1.429].
 33. Valente Duarte de Sousa IC, Tosti A. New investigational drugs for androgenetic alopecia. *Expert Opin Investig Drugs.* 2013 May; **22(5)**: 573-89. [PMID: 23550739]; [DOI: 10.1517/13543784.2013.784743].

34. Arora NS, Ramanayake T, Ren YF, Romanos GE. Platelet-rich plasma: A literatura review. *Implant Dent.* 2009 Aug; **18**(4): 303-10. [PMID: 19667818]; [DOI: 10.1097/ID.0b013e31819e8ec6].
35. Alves R, Grimalt R. A randomized placebo-controlled, double-blind, half-head study to assess the efficacy of platelet-rich plasma on the treatment of androgenetic alopecia. *Dermatol Surg* 2016; **42**: 491-7. [PMID: 27035501]; [DOI: 10.1097/DSS.0000000000000665].
36. Uebel CO, da Silva JB, Cantarelli D, Martins P. The role of platelet plasma growth factors in male pattern baldness surgery. *Plast Reconstr Surg.* 2006 Nov; **118**(6): 1458-66; discussion 1467. [PMID: 17051119]; [DOI: 10.1097/01.prs.0000239560.29172.33].
37. Maria-Angeliki G, Alexandros-Efstratios K, Dimitris R, Konstantinos K. Platelet-rich plasma as a potential treatment for noncicatricial alopecias. *Int J Trichology.* 2015 Apr-Jun; **7**(2): 54-63. [PMID: 26180449]; [DOI: 10.4103/0974-7753.160098].
38. Arshdeep, Kumaran MS. Platelet-rich plasma in dermatology: boon or a bane? *Indian J Dermatol Venereol Leprol.* 2014 Jan-Feb; **80**(1): 5-14. [PMID: 24448117]; [DOI: 10.4103/0378-6323.125467].
39. Lynch MD, Bashir S. Applications of platelet rich plasma in dermatology. A critical appraisal of the literature Journal of Dermatological Treatment. *J Dermatolog Treat.* 2015 Oct; **14**: 1-5. [PMID: 26466811]; [DOI: 10.3109/09546634.2015.1094178].
40. Marx RE. Platelet-rich plasma: evidence to support its use. *J Oral Maxillofac Surg.* 2004 Apr; **62**(4): 489-96. [PMID: 15085519]; [DOI: 10.1016/j.joms.2003.12.003].
41. Sánchez-González DJ, Méndez-Bolaina E, Trejo-Bahena NI. Platelet-rich plasma peptides: key for regeneration. *Int J Pept.* 2012; 32519. [PMID: 22518192]; [DOI: 10.1155/2012/532519].
42. Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: Implications for wound healing. *Plast Reconstr Surg.* 2004 Nov; **114**(6): 1502-8. [PMID: 15509939]; [DOI: 10.1097/01.PRS.0000138251.07040.51].
43. Weibrich G, Kleis WK, Hafner G, Hitzler WE. Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count. *J Craniomaxillofac Surg.* 2002 Apr; **30**(2): 97-102. [PMID: 12069512]; [DOI: 10.1054/jcms.2002.0285].
44. Badimon L, Vilahur G, and Padró, T. Lipoproteins, platelets, and atherothrombosis. *Rev Esp Cardiol.* 2009; **62**(10): 1161-78. [PMID: 19793522].
45. Schiavone G, Raskovic D, Greco J, Abeni D. Platelet-rich plasma for androgenetic alopecia: a pilot study. *Dermatol Surg.* 2014 Sep; **40**(9): 1010-9. [PMID: 25111436]; [DOI: 10.1097/01.DSS.0000452629.76339.2b].
46. Dhurat R, Sukesh M. Principles and methods of preparation of platelet-rich plasma: a review and author's perspective. *J Cutan Aesthet Surg.* 2014 Oct-Dec; **7**(4): 189-97. [PMID: 25722595]; [DOI: 10.4103/0974-2077.150734].
47. Takikawa M, Nakamura S, Nakamura S, Ishirara M, Kishimoto S, Sasaki K, Yanagibayashi S, Azuma R, Yamamoto N, Kiyosawa T. Enhanced effect of platelet rich plasma containing a new carrier on hair growth. *Dermatol Surg.* 2011 Dec; **37**(12): 1721-9. [PMID: 21883644]; [DOI: 10.1111/j.1524-4725.2011.02123.x].
48. Kang JS, Zheng Z, Choi MJ, Lee SH, Kim DY, Cho SB. The effect of CD34+ cell containing autologous platelet-rich plasma injection on pattern hair loss: A preliminary study. *J Eur Acad Dermatol Venereol.* 2014 Jan; **28**(1): 72-9. [PMID: 23279091]; [DOI: 10.1111/jdv.12062].
49. Evelyn-Evanthia Betsi, Esnault Germain, Daniel F. Kalbermaten, Mathias Tremp, Veronique Emmenegger. Platelet rich plasma injection is effective and safe for the treatment of alopecia. *Eur J Plast Surg* 2013 Jul; **36**(7)]; [DOI: 10.1007/s00238-013-0816-5].
50. Li ZJ, Choi HI, Choi DK, Sohn KC, Im M, Seo YJ, Lee YH, Lee JH, Lee Y. Autologous platelet-rich plasma: a potential therapeutic tool for promoting hair growth. *Dermatol Surg.* 2012 Jul; **38**: 1040-6. [PMID: 22455565]; [DOI: 10.1111/j.1524-4725.2012.02394.x].
51. Cervelli V, Garcovich S, Bielli A, Cervelli G4, Curcio BC1, Scioli MG3, Orlandi A3, Gentile P. The effect of autologous activated platelet rich plasma (AA-PRP) injection on pattern hair loss: Clinical and histomorphometric evaluation. *Biomed Res Int.* 2014. [PMID: 24883322]; [DOI: 10.1155/2014/760709].
52. Trink A, Sorbellini E, Bezzola P, Rodella L, Rezzani R, Ramot Y, Rinaldi F. A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata. *Br J Dermatol.* 2013 Sep; **169**(3): 690-4. [PMID: 23607773]; [DOI: 10.1111/bjd.12397].
53. Park KY, Kim HK, Kim BJ, Kim MN. Letter: Platelet-rich plasma for treating male pattern baldness. *Dermatol Surg.* 2012 Dec; **38**(12): 2042-4. [PMID: 23205550]; [DOI: 10.1111/dsu.12037].
54. Khatu SS, More YE, Gokhale NR, Chavhan DC, Bendsure N. Platelet-rich plasma in androgenetic alopecia: Myth or an effective tool. *J Cutan Aesthet Surg.* 2014 Apr; **7**(2): 107-10. [PMID: 25136212]; [DOI: 10.4103/0974-2077.138352].
55. Gkini MA, Kouskoukis AE, Tripsianis G, Rigopoulos D, Kouskoukis K. Study of platelet-rich plasma injections in the treatment of androgenetic alopecia through an one-year period. *J Cutan Aesthet Surg.* 2014 Oct; **7**(4): 213-9. [PMID: 25722600]; [DOI: 10.4103/0974-2077.150743].
56. Pietrzak WS, Eppley BL. Platelet rich plasma: biology and new technology. *J Craniofac Surg.* 2005 Nov; **16** (6): 1043-54. [PMID: 16327552]; [DOI: 10.1097/01.scs.0000186454.07097.bf].
57. Gentile P, Cole JP, Cole MA, Garcovich S, Bielli A, Scioli MG, Orlandi A, Insalaco C, Cervelli V. Evaluation of not-activated and activated PRP in hair loss treatment: Role of growth factor and cytokine concentrations obtained by different collection systems. *Int J Mol Sci.* 2017 Feb 14; **18**(2): [PMID: 28216604]; [DOI: 10.3390/ijms18020408].
58. Anitua E, Pino A, Martinez N, Orive G, Berridi D. The effect of plasma rich in growth factor on pattern hair loss: A pilot study. *Dermatol Surg.* 2017 May; **43** (5): 658-670. [PMID: 28221183]; [DOI: 10.1097/DSS.0000000000001049].
59. Gupta S, Revathi T N, Sacchidanand S, Nataraj H V. A study of the efficacy of platelet-rich plasma in the treatment of androgenetic alopecia in males. *Indian J Dermatol Venereol Leprol.* 2017; **83**: 412; [DOI: 10.4103/0378-6323.191128].
60. Gentile P, Garcovich S, Bielli A, Scioli MG, Orlandi A, Cervelli V. The effect of platelet-rich plasma in hair regrowth: A randomized placebo-controlled trial. *Stem Cells Transl Med.* 2015 Nov; **4**(11): 1317-23. [PMID: 26400925]; [DOI: 10.5966/sctm.2015-0107].
61. Singhal P, Agarwal S, Dhoot PS, Sayal SK. Efficacy of platelet-rich plasma in treatment of androgenic alopecia. *Asian J Transfus Sci.* 2015 Jul-Dec; **9**(2): 159-62. [PMID: 26420936]; [DOI: 10.4103/0973-6247.162713].
62. Mapar MA, Shahriari S, Haghighizadeh MH. Efficacy of platelet-rich plasma in the treatment of androgenetic (male-patterned) alopecia: A pilot randomized controlled trial. *J Cosmet Laser Ther.* 2016 Dec; **18**(8): 452-455. [PMID: 27593381]; [DOI: 10.1080/14764172.2016.1225963].
63. Puig CJ, Reese R, Peters M. Double-blind, placebo-controlled pilot study on the use of platelet-rich plasma in women with female androgenetic alopecia. *Dermatol Surg.* 2016 Nov; **42**(11): 1243-1247. [PMID: 27608205]; [DOI: 10.1097/DSS.0000000000000883].
64. Alves, R, Grimalt R. A Review of platelet-Rich plasma: History, biology, mechanism of Action, and classification. *Skin Appendage Disord.* 2017; **4**: 18-24. [PMID: 29457008]; [DOI: 10.1159/000477353].
65. Alves R, Grimalt R. Platelet-rich plasma in combination with 5% minoxidil topical solution and 1mg oral finasteride for the treatment of androgenetic alopecia: A randomized placebo-controlled, double-blind, half-head study. *Dermatol Surg.* 2017; **0**: 1-4.

- [PMID: 28562433]; [DOI: 10.1097/DSS.0000000000001198].
66. Xiao SE, Miao Y, Wang J, Jiang W, Fan ZX, Liu XM, Hu ZQ. As a carrier-transporter for hair follicle reconstitution, platelet-rich

plasma promotes proliferation and induction of mouse dermal papilla cells. *Sci Rep.* 2017 Apr 25; **7**(1): 1125. [PMID: 28442778]; [DOI: 10.1038/s41598-017-01105-8].